NEW YORK, NY / ACCESS Newswire / April 15, 2026 / Lifshitz Law Firm

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) as a result of the foregoing, INO-3107's overall regulatory and commercial prospects were overstated.